Back to Screener

Healthcare

BeiGene, Ltd.(BGNE)

Live Price

Offline

$184.71

+0.49% today

1Y Change

Window

No data

Market Cap
$20.21B
Revenue Growth
+40.2%
EPS Growth
+659.6%
Dividend Yield
0.0%
No coverage

Historical coverage is still loading

We are still backfilling 1Y daily history for this symbol. Some charts may stay empty until more data arrives.

No price data

Research Briefing

A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.

Decision context

Research Snapshot

BeiGene, Ltd. (BGNE) is a Healthcare stock with a market cap of $20.21B. The stock last traded around $184.71. Baseline metrics include revenue growth of +40.2%, EPS growth of +659.6%, a dividend yield of 0.0%. What stands out right now is revenue +40.2%, EPS +659.6%, free cash flow +240.6% with operating margin 8.4% and ROIC 4.8%. Valuation already assumes a fairly strong business story at P/E 171.9 and price/sales 6.7. Overall, the current profile looks closer to a higher-growth but lower-margin setup than a generic broad-market placeholder. Stock Foundry combines BGNE price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.

Sector Context

How this name stacks up against nearby peers on first-pass metrics.

Revenue Growth

Above sector median

+40.2% vs +7.6% peer median

Operating Margin

Below sector median

+8.4% vs +19.4% peer median

P/E

Above sector median

171.9 vs 36.3 peer median

What Changed This Quarter

Latest report context and the signals most likely to have changed the story.

Latest report is on the board

2026 was reported on Feb 26, 2026, but the surprise data is still limited.

The operating story is still moving forward

Revenue is running at +40.2% and EPS at +659.6%, with operating margin around 8.4%.

Benchmark Comparison

Normalized Performance vs SPY

Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.

1Y shared range

BGNE

Normalized return

SPY

S&P 500

Excess Return

Relative to SPY

BGNE Max Drawdown

Trailing 1Y

SPY Max Drawdown

Trailing 1Y

Benchmark comparison is loading or unavailable right now.

Calendar-Year Returns

Uses the longest available daily history for BGNE and SPY.

Calendar-year return history is still loading or unavailable.
BE

Company Overview

BeiGene, Ltd.

Last Updated
May 7, 2026

Key Fundamentals

Valuation, growth, profitability, and balance sheet signals.

Valuation

P/E
171.9
EV/EBITDA
60.3
Price/Sales
6.7
Price/Book
11.4

Growth

Revenue
+40.2%
EPS
+659.6%
Free Cash Flow
+240.6%

Profitability

Gross Margin
86.9%
Operating Margin
8.4%
Net Margin
5.4%
ROE
7.3%
ROIC
4.8%

Balance Sheet

Debt/Equity
0.46
Current Ratio
3.41

Earnings Reports

📅 Last reportedFeb 26, 2026
PeriodB/MEPSEPS ΔRevenueRev Δ
Feb 26, 26
0.59
Est
1498170.0B
Est
Nov 10, 25
1.09
Est
1412284.0B
Est
Aug 5, 25
0.84
Est
1315300.0B
Est
Nov 12, 24
-1.15
Est -0.88
-30.7%
1001599.0B
Est 1040702.1B
-3.8%
Aug 7, 24
-1.15
Est -2.10
+45.2%
929166.0B
Est 798330.0B
+16.4%
May 8, 24
-2.41
Est -2.98
+19.1%
751652.0B
Est 676450.0B
+11.1%
Feb 26, 24
-3.53
Est -2.36
-49.6%
634409.0B
Est 637013.3B
-0.4%
Nov 9, 23
2.01
Est -3.16
+163.6%
781308.0B
Est 596750.8B
+30.9%
Aug 2, 23
-3.64
Est -3.23
-12.7%
595261.0B
Est 501065.4B
+18.8%
May 4, 23
-3.34
Est -3.94
+15.2%
447801.0B
Est 444196.1B
+0.8%
Feb 27, 23
-4.29
Est -4.22
-1.7%
380095.0B
Est 388171.8B
-2.1%
Nov 9, 22
-5.39
Est -4.02
-34.1%
387628.0B
Est 385688.4B
+0.5%
Aug 4, 22
-5.56
Est -4.23
-31.4%
341572.0B
Est 313177.4B
+9.1%
May 5, 22
-4.24
Est -4.52
+6.2%
306626.0B
Est 260373.0B
+17.8%
Feb 25, 22
-6.16
Est -4.79
-28.6%
213979.0B
Est 214583.2B
-0.3%
Nov 4, 21
-4.46
Est -4.82
+7.5%
206440.0B
Est 189590.0B
+8.9%

Latest News

No news articles available

Official Releases

Company announcements and filings-style updates.

Official
No official releases available

Next Step

Keep the research moving

After the overview, the strongest next step is usually chart context or a tighter compare set.